LLY
Eli Lilly and Company · Healthcare · Drug Manufacturers - General
Momentum-Eingaben (vergleichbare Manager):
Halterbreite +9.1% ·
Aktienfluss -2.3% ·
neue Nettopositionen +8.3%
— Formel
Eigentümerfragmentierung — mehr Halter, kleinere Gesamtbeteiligung
Alle Eigentumszahlen: nur beobachtete 13F-Manager, Stammaktienpositionen, Berichtszeitraum Q3 2024
| Quartal | Inhaber | Δ | Aktien | Gemeldeter Wert | Neu | Ausstiege |
|---|---|---|---|---|---|---|
| Q2 2026 | 193 | +4 | 671.92M | $804.91B | +6 | −1 |
| Q1 2026 | 191 | -3 | 666.59M | $613.20B | +1 | −5 |
| Q4 2025 | 193 | +2 | 707.04M | $758.81B | +3 | — |
| Q3 2025 | 27 | -3 | 329.88M | $251.63B | +2 | −6 |
| Q2 2025 | 28 | -1 | 307.45M | $239.60B | +2 | −3 |
| Q1 2025 | 26 | 0 | 140.32M | $115.83B | +1 | −1 |
| Q4 2024 | 26 | +1 | 145.00M | $111.91B | +3 | −2 |
| Q3 2024 | 24 | +2 | 109.89M | $97.29B | +2 | — |
| Q2 2024 | 22 | — | 112.43M | $101.75B | — | — |
| # | Manager | Aktien | Δ Anteile | Wert | Deren Gewichtung | Gehalten | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 20.93M | +1.4% | $18.54B | 2.1% | ▲ Add | 2 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 20.93M | +1.4% | $18.54B | 2.1% | ▲ Add | 2 | SEC ↗ |
| 3 | Capital World Investors ✦ | 20.36M | -6.7% | $18.03B | 2.8% | ▼ Trim | 2 | SEC ↗ |
| 4 | PRIMECAP Management ✦ | 17.69M | -9.8% | $15.67B | 11.5% | ▼ Trim | 2 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passiv) | 17.09M | +0.5% | $15.09B | 1.2% | ▲ Add | 2 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passiv) | 17.09M | +0.5% | $15.09B | 1.2% | ▲ Add | 2 | SEC ↗ |
| 7 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 8 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 9 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 10 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 11 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 12 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 13 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 14 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 15 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 16 | Norges Bank ✦ (passiv) | 10.49M | -4.7% | $9.29B | 1.3% | ▼ Trim | 2 | SEC ↗ |
| 17 | Fisher Asset Management ✦ | 5.06M | +3.5% | $4.48B | 1.8% | ▲ Add | 2 | SEC ↗ |
| 18 | Arrowstreet Capital ✦ | 1.63M | +1.3% | $1.44B | 1.2% | ▲ Add | 2 | SEC ↗ |
| 19 | Millennium Management ✦ | 990.21K | +86.1% | $877.27M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 20 | Tiger Global Management ✦ | 969.80K | +4.3% | $859.18M | 3.7% | ▲ Add | 2 | SEC ↗ |
| 21 | Marshall Wace ✦ | 910.13K | +15.3% | $806.32M | 1.1% | ▲ Add | 2 | SEC ↗ |
| 22 | Marshall Wace ✦ | 910.13K | +15.3% | $806.32M | 1.1% | ▲ Add | 2 | SEC ↗ |
| 23 | Marshall Wace ✦ | 910.13K | +15.3% | $806.32M | 1.1% | ▲ Add | 2 | SEC ↗ |
| 24 | Adage Capital Partners ✦ | 829.38K | +0.2% | $734.78M | 1.3% | ▲ Add | 2 | SEC ↗ |
| 25 | AQR Capital Management ✦ | 677.64K | +42.8% | $591.79M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 26 | AQR Capital Management ✦ | 677.64K | +42.8% | $591.79M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 27 | AQR Capital Management ✦ | 677.64K | +42.8% | $591.79M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 28 | AQR Capital Management ✦ | 677.64K | +42.8% | $591.79M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 29 | AQR Capital Management ✦ | 677.64K | +42.8% | $591.79M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 30 | D. E. Shaw & Co. ✦ | 408.08K | +72.0% | $361.54M | 0.5% | ▲ Add | 2 | SEC ↗ |
| 31 | D. E. Shaw & Co. ✦ | 408.08K | +72.0% | $361.54M | 0.5% | ▲ Add | 2 | SEC ↗ |
| 32 | Renaissance Technologies ✦ | 257.81K | Neu | $228.41M | 0.3% | New | 1 | SEC ↗ |
| 33 | Coatue Management ✦ | 247.95K | +19.8% | $219.67M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 34 | Coatue Management ✦ | 247.95K | +19.8% | $219.67M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 35 | Coatue Management ✦ | 247.95K | +19.8% | $219.67M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 36 | Coatue Management ✦ | 247.95K | +19.8% | $219.67M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 37 | Coatue Management ✦ | 247.95K | +19.8% | $219.67M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 38 | Citadel Advisors ✦ | 215.18K | -57.0% | $190.64M | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 39 | Citadel Advisors ✦ | 215.18K | -57.0% | $190.64M | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 40 | Two Sigma Investments ✦ | 199.74K | -11.5% | $176.95M | 0.4% | ▼ Trim | 2 | SEC ↗ |
| 41 | Viking Global Investors ✦ | 152.04K | +5.5% | $134.70M | 0.5% | ▲ Add | 2 | SEC ↗ |
| 42 | Bridgewater Associates ✦ | 73.27K | -23.5% | $64.91M | 0.4% | ▼ Trim | 2 | SEC ↗ |
| 43 | Dodge & Cox ✦ | 45.09K | -1.9% | $39.95M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 44 | GAMCO Investors ✦ | 34.81K | -2.8% | $30.84M | 0.3% | ▼ Trim | 2 | SEC ↗ |
| 45 | Point72 Asset Management ✦ | 13.16K | Neu | $11.66M | 0.0% | New | 1 | SEC ↗ |
| 46 | Gotham Asset Management ✦ | 8.52K | -28.7% | $7.54M | 0.1% | ▼ Trim | 2 | SEC ↗ |
„Ihre Gewichtung" = Anteil der Position am gemeldeten 13F-Eigenkapitalwert des jeweiligen Managers — das Conviction-Maß. ✦ = kuratorisch ausgewählter Manager.
Neue Käufer
| Renaissance Technologies | $228.41M | 0.3% |
| Point72 Asset Management | $11.66M | 0.0% |
Ausgestiegen
| Keine erfassten Ausstiege in diesem Quartal. |
Marktweiter Kontext: über ALLE 13F-Melder (strukturierte SEC-Daten, Q1 2026): 4,323 Inhaber, 762.84M Anteile, $674.93B gemeldet. Dies ist ein anderer, älterer Zeitraum als die oben genannten Zahlen des erfassten Universums; beide werden niemals vermischt.
Was die erfassten Halter dieses Wertpapiers am häufigsten sonst noch halten — Zählungen gemeinsamer Eigentümerschaft, keine fundamentalen Zusammenhänge.
Käufe auf dem offenen Markt (P)
Keine Insider-Käufe auf dem offenen Markt in unserem Erfassungszeitraum.
Verkäufe auf dem offenen Markt (S)
Officer · 6.50K Ant. · $7.64M
Officer · 2.00K Ant. · $2.37M
Officer · 5.00K Ant. · $5.95M
Zuteilungen, Ausübungen und Steuereinbehalte werden hier nie als Käufe oder Verkäufe gezählt. Methodik
The Food and Drug Administration has cleared a new blood test from Roche and Eli Lilly designed to help identify…
ForbesThe Food and Drug Administration cleared a blood test for identifying Alzheimer's disease symptoms, which was developed…
WSJThe U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood test to help identify signs of…
ReutersThe once-daily pill was approved for patients with a body mass index of at least 30, or between 27 and 30 in the event…
WSJEli Lilly said on Monday it has launched its oral pill, Foundayo, in the UK for weight management and type 2…
Reuters